Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants
Gerald W.L., Ladanyi M., de Alava E., et al. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J Clin Oncol 16 (1998) 3028-3036
Desmoplastic small round cell tumor: I. A histopathologic study of 39 cases with emphasis on unusual histological patterns
Ordonez N.G. Desmoplastic small round cell tumor: I. A histopathologic study of 39 cases with emphasis on unusual histological patterns. Am J Surg Pathol 22 (1998) 1303-1313
Desmoplastic small round cell tumor: report of a case presenting as a primary ovarian neoplasm
Parker L.P., Duong J.L., Wharton J.T., et al. Desmoplastic small round cell tumor: report of a case presenting as a primary ovarian neoplasm. Eur J Gynaecol Oncol 23 (2002) 199-202
The Ewing's family of tumors (EFT) express the tyrosine kinase receptors, kit and PDGF-R
[abstr 3321]
Chow W.A.C.P., and Doroshow J.H. The Ewing's family of tumors (EFT) express the tyrosine kinase receptors, kit and PDGF-R. Proc Am Soc Clin Oncol (2003) 826 [abstr 3321]
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. desmoplastic small round-cell tumors
Sandberg A.A., and Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. desmoplastic small round-cell tumors. Cancer Genet Cytogenet 138 (2002) 1-10
Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101
Adamson P.C., Blaney S.M., Widemann B.C., et al. Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemother Pharmacol 53 (2004) 482-488
Phase 2 trial of Imatinib mesylate (IM) for treatment of recurrent or refractory pediatric solid tumors; a Children's Oncology Group Study. 2005 ASCO Annual Meeting Proccedings
Bond M., M.L.B., Pappo A., Schultz K.R., Krailo M., Fouladi M., et al. Phase 2 trial of Imatinib mesylate (IM) for treatment of recurrent or refractory pediatric solid tumors; a Children's Oncology Group Study. 2005 ASCO Annual Meeting Proccedings. J. Clin. Oncol. 23 Suppl. 16 (2005) S8520